Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials
Open Access
- 24 May 2023
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (2) , 371-380
Abstract
Rozibafusp alfa (AMG 570) is a first‐in‐class bispecific IgG2‐peptide fusion designed to inhibit inducible T‐cell costimulator ligand (ICOSL) and B‐cell activating factor (BAFF). The pharmacokinetics (PK) and pharmacodynamics (PD) of rozibafusp alfa were investigated in two randomized, placebo‐controlled clinical studies: a phase Ia single ascending‐dose study (7–700 mg subcutaneously (s.c.)) in healthy subjects and a phase Ib multiple ascending‐dose study (70–420 mg s.c. every 2 weeks (q2w)) in patients with rheumatoid arthritis. Rozibafusp alfa exhibited nonlinear PK and dose‐related and reversible dual‐target engagement. Maximal reduction of naïve B cells from baseline (> 40%), reflective of BAFF inhibition, was achieved with rozibafusp alfa exposure (area under the concentration‐time curve from time 0 to time infinity (AUCinf) and AUC within a dosing interval from day 0 to day 14 (AUCtau)) above 51 and 57 days•μg/mL for the single‐dose (≥ 70 mg) and multiple‐dose studies (≥ 70 mg q2w), respectively. ICOSL receptor occupancy on circulating B cells, a surrogate PD end point for ICOSL inhibition, was directly related to drug concentration. PK/PD analysis showed > 90% RO at rozibafusp alfa ≥ 22.2 μg/mL (≥ 420‐mg single dose or ≥ 210 mg q2w multiple dose), with saturation occurring at higher drug concentrations. These results informed the design and dose selection of a phase IIb study assessing the safety and efficacy of rozibafusp alfa in patients with active systemic lupus erythematosus.Keywords
This publication has 25 references indexed in Scilit:
- Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy SubjectsClinical Pharmacology in Drug Development, 2013
- Population Pharmacokinetics of Belimumab Following Intravenous Administration in Patients With Systemic Lupus ErythematosusThe Journal of Clinical Pharmacology, 2013
- Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging StudyThe Journal of Rheumatology, 2013
- Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?Expert Opinion on Drug Metabolism & Toxicology, 2012
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- ICOS Receptor Instructs T Follicular Helper Cell versus Effector Cell Differentiation via Induction of the Transcriptional Repressor Bcl6Immunity, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2009
- A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care & Research, 2009
- Functional Half-Life is a Meaningful??Descriptor of Steady-State??Pharmacokinetics of??an??Extended-Release Formulation of??a??Rapidly Cleared DrugClinical Drug Investigation, 2006